Compare · ENCP vs TMO
ENCP vs TMO
Side-by-side comparison of Energem Corp (ENCP) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- ENCP operates in Energy, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $174.49B, about 1181.5x ENCP ($147.7M).
- TMO has hit the wire 6 times in the past 4 weeks while ENCP has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 0 for ENCP).
- Company
- Energem Corp
- Thermo Fisher Scientific Inc
- Price
- $12.28-0.28%
- $469.57+0.63%
- Market cap
- $147.7M
- $174.49B
- 1M return
- -
- -4.31%
- 1Y return
- -
- +11.45%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
Energem Corp
Energem Corp. does not have significant operations. The company focuses on effecting a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus a target business operating in the energy industry. The company was incorporated in 2021 and is based in Kuala Lumpur, Malaysia.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest ENCP
- SEC Form 10-K filed by Energem Corp
- Energem Corp filed SEC Form 8-K: Leadership Update
- SEC Form NT 10-K/A filed by Energem Corp (Amendment)
- SEC Form SC 13G/A filed by Energem Corp (Amendment)
- Energem Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form NT 10-K filed by Energem Corp
- Energem Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Leadership Update, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status
- SEC Form 25-NSE filed by Energem Corp
- Graphjet Technology, The World's Only Direct Biomass-to-Graphite Producer, Completes Transaction and Will Begin Trading on Nasdaq
- SEC Form 425 filed by Energem Corp
Latest TMO
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026
- SEC Form 4 filed by Sperling Scott M
- SEC Form 4 filed by Keith R. Alexandra
- SEC Form 4 filed by Lynch Karen S